

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 31.12.2025	Preceeding 3 months ended 30.09.2025	Corresponding 3 months ended 31.12.2024	9 months ended 31.12.2025	9 months ended 31.12.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	102259	97363	94636	280105	275741	372349
2	Other income	3182	3127	3506	10685	10310	14256
3	Total Income (1+2)	105441	100490	98142	290790	286051	386605
	Expenses						
	(a) Cost of materials consumed	7010	10707	9193	29860	36251	47086
	(b) Purchases of stock-in-trade	21727	23271	16423	68205	55371	84511
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	6171	1076	9528	694	10464	5123
	(d) Employee benefits expense	15188	13805	12474	44250	42673	57970
	(e) Finance costs	119	51	9	212	73	131
	(f) Depreciation and amortisation expense	2032	1743	1880	5327	5207	6679
	(g) Other expenses	15405	15036	18000	41795	47127	60730
4	Total expenses	67652	65689	67507	190343	197166	262230
5	Profit before exceptional items and tax (3-4)	37789	34801	30635	100447	88885	124375
6	Exceptional items (credit) (Refer Note 2)	-	264	-	264	469	469
7	Profit before tax (5+6)	37789	35065	30635	100711	89354	124844
8	Tax expense						
	(a) Current tax	9865	9521	7305	26771	23384	32318
	(b) Deferred tax	206	44	472	252	78	620
9	Profit for the period/year (7-8)	27718	25500	22858	73688	65892	91906

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 31.12.2025	Preceeding 3 months ended 30.09.2025	Corresponding 3 months ended 31.12.2024	9 months ended 31.12.2025	9 months ended 31.12.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	829	-	157	829	157	(355)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(209)	-	(39)	(209)	(39)	89
11	Total comprehensive income for the period (9+10)	28338	25500	22976	74308	66010	91640
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941
	Other equity						177982
	Earnings per share (EPS) (of Rs. 10 each)						
	Basic and diluted EPS before Exceptional items (Rs.)	16.36	14.92	13.49	43.36	38.66	54.01
	Basic and diluted EPS after Exceptional items (Rs.)	16.36	15.06	13.49	43.50	38.89	54.24
Not Annualised							

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09th February 2026. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter and nine months ended 31st December 2025.
2. Exceptional items credit for the period ended 31st December 2025 of Rs. 264 lakhs and for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties
3. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.
The Company has assessed and disclosed the incremental impact of these changes on the basis of actuarial valuation report. This has resulted in an increase of Rs. 1182 lakhs in Employee Benefits expense for the quarter and nine months ended December 31, 2025. The incremental impact primarily arises due to change in wage definition.
The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
4. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

09th February, 2026

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346